- Home
- LFLY vs SCNI Comparison
LFLY vs SCNI Comparison
Compare LFLY & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFLY
- SCNI
- Stock Information
- Founded
- LFLY 2010
- SCNI 2003
- Country
- LFLY United States
- SCNI Israel
- Employees
- LFLY N/A
- SCNI N/A
- Industry
- LFLY Computer Software: Prepackaged Software
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LFLY Technology
- SCNI Health Care
- Exchange
- LFLY Nasdaq
- SCNI Nasdaq
- Market Cap
- LFLY 4.0M
- SCNI 3.5M
- IPO Year
- LFLY N/A
- SCNI N/A
- Fundamental
- Price
- LFLY $1.54
- SCNI $2.84
- Analyst Decision
- LFLY Strong Buy
- SCNI
- Analyst Count
- LFLY 2
- SCNI 0
- Target Price
- LFLY $7.59
- SCNI N/A
- AVG Volume (30 Days)
- LFLY 47.8K
- SCNI 12.9K
- Earning Date
- LFLY 11-07-2024
- SCNI 11-29-2024
- Dividend Yield
- LFLY N/A
- SCNI N/A
- EPS Growth
- LFLY N/A
- SCNI N/A
- EPS
- LFLY N/A
- SCNI N/A
- Revenue
- LFLY $35,868,000.00
- SCNI $284,000.00
- Revenue This Year
- LFLY N/A
- SCNI N/A
- Revenue Next Year
- LFLY N/A
- SCNI N/A
- P/E Ratio
- LFLY N/A
- SCNI N/A
- Revenue Growth
- LFLY N/A
- SCNI N/A
- 52 Week Low
- LFLY $1.32
- SCNI $2.23
- 52 Week High
- LFLY $6.49
- SCNI $8.92
- Technical
- Relative Strength Index (RSI)
- LFLY 39.51
- SCNI 30.31
- Support Level
- LFLY $1.32
- SCNI $2.91
- Resistance Level
- LFLY $1.87
- SCNI $3.70
- Average True Range (ATR)
- LFLY 0.19
- SCNI 0.21
- MACD
- LFLY -0.01
- SCNI -0.07
- Stochastic Oscillator
- LFLY 32.74
- SCNI 7.37
About LFLY Leafly Holdings Inc.
Leafly Holdings Inc operates an online cannabis information resource platform. It offers cannabis retailers and brands subscription-based marketplace listings that provide its cannabis audience with information, reviews, menus, and ordering and delivery options through legal retailers.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.